— Intravenous cefepime-zidebactam was significantly superior to meropenem in phase III trial
June 4, 2026
• 2 min read
The FDA approved intravenous cefepime and zidebactam (Zaynich) for complicated urinary tract infections (UTIs), including pyelonephritis, caused by susceptible gram-negative bacteria in adults, Wockhardt announced.
The novel antibiotic pairs a cephalosporin (cefepime) with a non-beta-lactam antibacterial and beta-lactamase inhibitor (zidebactam) to target a wide range of multidrug-resistant and extensively drug-resistant gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae complex, and Pseudomonas aeruginosa.
